CLINICAL TRIAL: ADMINISTRATION OF PERIPHERAL BLOOD T-CELLS AND EBV SPECIFIC CTLS

临床试验：外周血 T 细胞和 EBV 特异性 CTLS 的施用

• 批准号: 8166662
• 负责人: CHRYSTAL U LOUIS
• 金额: $ 0.5万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166662
• 关键词: Autologous; Cells; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; EBV-Specific Cytotoxic T-Lymphocyte; Funding; Grant; Institution; Monoclonal Antibodies; Neuroblastoma; PTPRC gene; Patients; Research; Research Personnel; Resources; Safety; Source; T-Lymphocyte; United States National Institutes of Health; cell type; in vivo; peripheral blood; receptor; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate the safety of escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma who have been lymphodepleted by CD45 monoclonal antibodies (MAbs). Secondary Objectives To determine the differential survival and function of these two infused cell-types in vivo, in particular to determine if chimeric receptor transduced EBV-CTLs survive longer than transduced peripheral-blood T-cells. To determine anti-tumor effects of transduced peripheral blood T-cells and EBV specific CTLs in vivo.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 评价向已被CD 45单克隆抗体（MAb）淋巴细胞耗竭的神经母细胞瘤患者施用递增剂量的14g2a.zeta嵌合受体转导的自体EBV特异性细胞毒性T淋巴细胞（EBV-CTL）和14g2a.zeta转导的自体外周血T细胞的安全性。 次要目的 确定这两种输注细胞类型在体内的差异存活和功能，特别是确定嵌合受体转导的EBV-CTL是否比转导的外周血T细胞存活更长。 确定转导的外周血T细胞和EBV特异性CTL的体内抗肿瘤作用。